MEDIUM confidence: 100% data completeness, but the composite (52) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$345.7M over 180 days (0 open-market buys, 9 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Avg target $112 (last qtr, 16 analysts) → $116 (last mo, 5) (+3.3%).
Buy-rated share 86% → 89% over ~3 months (+3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.87 | $2.58 | +38.0% |
| May 2026 | $2.21 | $2.57 | +16.3% |
| Feb 2026 | $1.00 | $1.09 | +9.0% |
| Oct 2025 | $1.37 | $1.60 | +16.8% |
| Jul 2025 | $1.46 | $1.81 | +24.0% |
| May 2025 | $1.70 | $2.25 | +32.4% |
| Feb 2025 | $0.91 | $1.19 | +30.2% |
| Nov 2024 | $1.44 | $1.09 | -24.3% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $292.1B— | $322.5B+10.4% | $357.8B+10.9% | $372.8B+4.2% | $402.1B+7.8% |
| EPS (dil.) | $5.95— | $3.26-45.2% | $6.47+98.5% | $3.66-43.4% | $1.39-62.0% |
| Free Cash Flow | $15.7B— | $13.4B-14.6% | $10.4B-22.7% | $6.3B-39.1% | $7.8B+23.4% |
| Gross Margin | 17.8% | 16.9%-0.9pp | 15.2%-1.7pp | 13.8%-1.4pp | 13.8%-0.0pp |
| Operating Margin | 4.6% | 2.5%-2.1pp | 3.8%+1.4pp | 2.3%-1.6pp | 2.6%+0.3pp |
| Net Margin | 2.7% | 1.3%-1.4pp | 2.3%+1.0pp | 1.2%-1.1pp | 0.4%-0.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 4.9%/yr (revenue basis).
Base free cash flow $8.2B (avg FY2023–FY2025; latest year $7.8B) · equity value $121.8B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 52 indicates a neutral outlook for CVS Health Corp, with no significant divergence between long-term and short-term scores. The stock scores high on value, with a P/E of 24.9 and P/B of 1.5, and exhibits low risk, with a beta of 0.6. However, growth scores are dragged down by a decline in EPS growth of 61.7%, while momentum is mixed, with a strong 12-month return of 46.2% but a recent 3-month decline of 2.4%.